Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
—
—
—
Sakar Healthcare ltd. is engaged in providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Liquid Injectables in ampoules and vials, and Dry Powder Injections.
Customise key metrics, see detailed forecasts, download stock data and more
Pledged promoter holdings is insignificant
In last 3 months, mutual fund holding of the company has almost stayed constant
SAKAR HEALTHCARE LIMITED has informed the Exchange about Notice of Shareholders Meeting for Extra-ordinary Meeting to be held on 20-Dec-2023 | Download
SAKAR HEALTHCARE LIMITED has informed the Exchange about Notice of Shareholders Meeting for Extra-ordinary Meeting to be held on 20-Dec-2023 | Download
Sakar Healthcare Limited has informed the Exchange about Issuance of Equity Shares and Warrants by way of preferential issue to Promoter and Non-Promoter Group Categories | Download
Sakar Healthcare Limited has informed the Exchange about Issuance of Equity Shares and Warrants by way of preferential issue to Promoter and Non-Promoter Group Categories | Download
Decreased Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has decreased by 6.57%